Takeda Pharmaceutical Company Limited - SIC # 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS

Ticker Exchange SIC # Website Latest Ticker
TAK New York 8733 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

Denali to Sell Priority Review Voucher for $195M Cash Boost - Jun 19th, 2026 6:40 am
Boltz Announces Collaboration with Takeda to Deploy Frontier Biomolecular AI Models Across Takeda's Research Organization - Jun 18th, 2026 8:03 am
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight - Jun 18th, 2026 8:01 am
Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis - Jun 16th, 2026 12:13 pm
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 - Jun 15th, 2026 10:00 am
AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus - Jun 15th, 2026 8:54 am
Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test. - Jun 11th, 2026 2:15 pm
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations - Jun 11th, 2026 5:00 am
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Jun 11th, 2026 1:00 am
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Jun 10th, 2026 12:08 pm
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease - Jun 9th, 2026 2:30 pm
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton - Jun 9th, 2026 6:16 am
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases - Jun 5th, 2026 2:55 am
Adlib Appoints Kristen Sauter as President & GM of Life Sciences to Accelerate Its Vertical AI Strategy - Jun 4th, 2026 6:00 am
Otsuka showcases kidney drug data; Pfizer cuts an AI deal - Jun 4th, 2026 3:22 am
Is Takeda Pharmaceutical Company Limited (TAK) Facing Major Legal Risk After U.S. Jury Rules on Generic Drug Delay? - Jun 2nd, 2026 7:56 am
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading - Jun 1st, 2026 8:40 am
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer - May 31st, 2026 6:00 pm
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC - May 31st, 2026 6:00 pm
Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | DelveInsight - May 28th, 2026 8:01 am